Sanjiv Sam Gambhir, MD, PhD

Publication Details

• Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.

  Xu Y, Chang E, Liu H, Jiang H, Gambhir SS, Cheng Z. J Nucl Med. 2012; 53 (2): 312-7

  Cerenkov luminescence imaging (CLI) has emerged as a less expensive, easier-to-use, and higher-throughput alternative to other nuclear imaging modalities such as PET. It is expected that CLI will find many applications in biomedical research such as cancer detection, probe development, drug screening, and therapy monitoring. In this study, we explored the possibility of using CLI to monitor drug efficacy by comparisons against PET. To assess the performance of both modalities in therapy monitoring, 2 murine tumor models (large cell lung cancer cell line H460 and prostate cancer cell line PC3) were given bevacizumab versus vehicle treatments. Two common radiotracers, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) and (18)F-FDG, were used to monitor bevacizumab treatment efficacy.

  PubMedID: 22241909